Brief: Harbour BioMed Doses First Patient In Phase I Trial Of B7H4x4-1BB Bispecific Antibody
25/05/2022 12:49
May 25 (Reuters) - HBM Holdings Ltd 2142.HK :
* HARBOUR BIOMED ANNOUNCES DOSING OF FIRST PATIENT IN PHASE
I
TRIAL OF B7H4X4-1BB BISPECIFIC ANTIBODY
Source text for Eikon: ID:nPn2zhsjRa
Further company coverage: 2142.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study